PHYSIOLOGICALY BASED PHARMACOKINTEIC MODELLING OF 18F-DCFPYL TO PREDICT THE TISSUE DISTRIBUTION IN PATIENTS WITH PROSTATE CANCER

Abstract

Introduction: The goal of this study was to develop a whole body physiological based pharmacokinetic-model (PBPK-model) to predict the tissue distribution of 18F-DCFPyL in patients with prostate cancer (PCa).

Method: The model was extended from a previously published PBPK-model describing PCa patients to predict the tissue distribution of 18F-DCFPyL. This model describes the tumors and organs at risks. The model was simulated and the results were compared to literature observations of patients with metastatic PCa.

Results: Our model adequately predicted the distribution of 18F-DCFPyL. Sensitivity analysis showed that the receptor densities, tumor flow and haematocrit had significant influence on the model outcome. The release and degradation of 18F-DCFPyL, and total organ volumes showed no significant influence on the outcome.

Discussion: The tumor flow, receptor densities and haematocrit should be measured in the future to accurately predict tissue distribution. The release and degradation of 18F-DCFPyL, and total organ volumes can be fixed on literature data.

Conclusion: The final PBPK-model was able to adequately predict tissue distribution of 18F-DCFPyL.